1[1]Judith ME,Nancy C,Dolan PC.Update in women's health[J].Ann Intern Med,2000,133(10):808-814
2[2]Seltzer V.Cancer screening in the postmenopausal women[J].Clin Obstet Gynecol,1996,39(4):889-892
3[3]Muto MG,Cramer DW,Brown DL,et al.Screening for ovarian cancer:The preliminary experience of a familial ovarian cancer center[J].Gynecol Oncol,1993,51:12-16
4[4]Menon U,Talaat A,Rosenthal AN.Performance of ultrasound as a second line test to serum CA125 in ovarian cancer screening[J].Br J Obstet Gynecol,2000,107(2):165
5[5]Sassone AM,Timor-Tritsch IE,Artner A,et al.Transvaginal sonographic characterization of ovarian diseases:Evaluation of a new scoring system to predict malignancy[J].Obstet Gynecol,1991,78:70-76
6[6]Lerner JP,Timor-Tristch IE,Federmam A,et al.Transvaginal ultrasonographic characterization of ovarian masses with an improved,weighted scoring system[J].Am J Obstet Gynecol,1994,170:81-87
7[7]Gleischer AC,Rodgers WH,Rao BK,et al.Assessment of ovarian tumor vascularity with transvaginal clolr Doppler sonography[J].J Ultrasound Med,1991,10:563-567
8[8]Carter JR,Lau M,Fowler JM,et al.Blood flow characteristics of ovarian tumors:Implications for ovarian cancer screening[J].Am J Obstet Gynecol,1995,172:901-905
9[9]Suzuki S,Moore DH,Gray JW.An approach to analysis of large-scale correlations between genome changes and clinical endpoints in ovarian cancer[J].Cancer Res,2000,60(19):5382-5385
10[10]Darnell JC,Albert ML,Darnell RB.Cdr2,a target antigen of naturally occurring human trmor immunity,is widely expressed in gynecological tumors[J].Cancer Res,2000.60(8):2136
